title: Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial.
abstract: BACKGROUND
  Nitrates are widely used in the treatment of angina in patients with acute myocardial infarction (AMI). Short-term administration prevents left ventricular (LV) dilation and infarct expansion. However, little information is available regarding their long-term effects on LV remodeling in patients surviving Q-wave AMI.
  
  
  RESULTS
  This was a randomized, double-blind, placebo-controlled trial designed to investigate the long-term (6-month) efficacy of intermittent transdermal nitroglycerin (NTG) patches on LV remodeling in 291 survivors of AMI. Patients meeting entry criteria had baseline gated radionuclide angiography (RNA) followed by randomization to placebo or active NTG patches delivering 0.4-, 0.8-, or 1.6-mg/h. RNA was repeated at 6 months and 6.5 days after withdrawal of double-blind medication. The primary study end point was the change in end-systolic volume index (ESVI). Both ESVI and end-diastolic volume index (EDVI) were significantly reduced with 0.4-mg/h NTG patches (-11.4 and -11.6 mL/m2, respectively, P<.03). This beneficial effect was observed primarily in patients with a baseline LV ejection fraction < or =40% (deltaESVI, -31 mL/m2; deltaEDVI, -33 mL/m2; both P<.05) and only at the 0.4-mg/h dose. After NTG patch withdrawal, ESVI significantly increased but did not reach pretreatment values.
  
  
  CONCLUSIONS
  Transdermal NTG patches prevent LV dilation in patients surviving AMI. The beneficial effects are limited to patients with depressed LV function and only at the lowest (0.4-mg/h) dose. Continued administration is necessary to maintain efficacy. Whether these remodeling effects confer a clinical or survival advantage will need to be addressed in an adequately powered cardiac event trial.
authors.affiliation: Baylor College of Medicine, Houston, Tex, USA. johnj@bcm.tmc.edu
authors.forename: J J
authors.initials: JJ
authors.lastname: Mahmarian
authors.forename: L A
authors.initials: LA
authors.lastname: Moyé
authors.forename: D A
authors.initials: DA
authors.lastname: Chinoy
authors.forename: R F
authors.initials: RF
authors.lastname: Sequeira
authors.forename: G B
authors.initials: GB
authors.lastname: Habib
authors.forename: W J
authors.initials: WJ
authors.lastname: Henry
authors.forename: A
authors.initials: A
authors.lastname: Jain
authors.forename: B R
authors.initials: BR
authors.lastname: Chaitman
authors.forename: C S
authors.initials: CS
authors.lastname: Weng
authors.forename: H
authors.initials: H
authors.lastname: Morales-Ballejo
authors.forename: C M
authors.initials: CM
authors.lastname: Pratt
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002306:Cardiac Volume / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D005996:Nitroglycerin / Q000008:administration & dosage*; D011446:Prospective Studies; D014665:Vasodilator Agents / Q000008:administration & dosage*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D014665:Vasodilator Agents; D005996:Nitroglycerin